According to the Administrator, CMS has taken "historic action" to expand access to full-spectrum CBD and has created mechanisms allowing certain participating healthcare entities to furnish eligible hemp products to patients. MMJ believes healthcare policy involving cannabinoid products should be driven by scientific evidence, product characterization and patient safety rather than political or commercial pressure. MMJ has also pursued analytical characterization, stability work, FDA IND programs, FDA Orphan Drug Designation and DEA controlled-substance registrations. MMJ believes CMS should publicly answer several basic questions before expanding cannabinoid access among Medicare beneficiaries:What product-specific toxicology evidence did CMS review? But Medicare beneficiaries should not become the population in which unanswered questions about commercial cannabinoid products are discovered after widespread exposure."